Interleukin 23 inhibitors for psoriasis: not just another number

The Lancet

Volumn 390, Issue 10091, 2017, Pages 208-210

  Bachelez, Hervé ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; GUSELKUMAB; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23P19; RISANKIZUMAB; TILDRAKIZUMAB; USTEKINUMAB; INTERLEUKIN 23;

ANTIINFLAMMATORY ACTIVITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; IMMUNOPATHOGENESIS; NOTE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN GLOBAL ASSESSMENT SCORE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SKIN DISEASE ASSESSMENT; TH1 CELL; TREATMENT RESPONSE;

HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; PSORIASIS;

EID: 85020167395     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31474-5     Document Type: Note

References (11)

1. Lowes, MA, Suárez-Fariñas, M, Krueger, JG, Immunology of psoriasis. Ann Rev Immunol 32 (2014), 227–255.
2. Bachelez, H, Interleukin-17 inhibition: the route to psoriasis clearance?. Lancet 386 (2015), 510–512.
3. Gaffen, SL, Jain, R, Garg, AV, Cua, DJ, The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol 14 (2014), 585–600.
4. Blauvelt, A, Papp, KA, Griffiths, CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76 (2017), 405–417.
5. Reich, K, Armstrong, AW, Foley, P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76 (2017), 418–431.
6. Papp, KA, Blauvelt, A, Bukhalo, M, et al. Risankizumab vs ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 376 (2017), 1551–1560.
7. Kopp, T, Riedl, E, Bangert, C, Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 521 (2015), 222–226.
8. Reich, K, Papp, KA, Blauvelt, A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet, 2017 published online June 5. http://dx.doi.org/10.1016/S0140-6736(17)31279-5.
9. Harden, JL, Johnson-Huang, LM, Chamian, MF, et al. Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol 135 (2015), 553–556.
10. Saunte, DM, Mrowietz, U, Puig, L, Zachariae, C, Candida infections in psoriasis and psoriatic arthritis patients treated with IL-17 inhibitors and their practical management. Br J Dermatol, 2016, 10.1111/bjd.15015 published online Aug 31.
11. Reich, K, Leonardi, C, Langley, RG, et al. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol 76 (2017), 441–448.